LB14. Efficacy and Immunogenicity of an Ad26.RSV.preF-based Vaccine in the Prevention of RT-PCR-confirmed RSV-mediated Lower Respiratory Tract Disease in Adults Aged ≥65 Years: A Randomized, Placebo-controlled, Phase 2b Study

BACKGROUND: Respiratory syncytial virus (RSV) can cause serious lower respiratory tract disease (LRTD) in older adults. Despite a high burden of disease, there is currently no licensed vaccine for RSV. Here, we report the primary efficacy and immunogenicity results from a Phase 2b proof-of-concept t...

Descripción completa

Detalles Bibliográficos
Autores principales: Falsey, Ann R, Williams, Kristi, Gymnopoulou, Efi, Bart, Stephan A, Ervin, John E, Bastian, Arangassery Rosemary, Menten, Joris, De Paepe, Els, de Boer, Hilde, Vandenberghe, Sjoukje, Chan, Eric, Sadoff, Jerald, Douoguih, Macaya, Callendret, Benoit, Comeaux, Christy, Heijnen, Esther
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Late Breaker Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644287/
http://dx.doi.org/10.1093/ofid/ofab466.1650

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644287/
http://dx.doi.org/10.1093/ofid/ofab466.1650

Ejemplares similares